Previous studies have demonstrated that serum levels of the peptide hormone LEAP2 are markedly elevated in patients with metabolic dysfunction-associated steatohepatitis, whereas only moderate increase was observed in simple steatosis. Here, LEAP2 is linked to steatosis.